Major Trials Alter Standards for Anticoagulant Therapy in PAD and Valve Replacement

DECLARE-TIMI 58 Sub-analyses: Expanding Evidence of Cardiovascular Protection across Broad Spectrum of Patients

Earlier Treatment Intervention in Heart Failure Patients Results in Improved Outcomes

PCSK9 Inhibitors Outcomes Data: Definitive CV Protection

Reduced All-Cause Death Suggests SGLT-2 Inhibitors May Be Part of New Anti-Diabetes Standard

Increasing NT-proBNP Isolated as Surrogate for Adverse Outcomes in Heart Failure

Emerging Outcomes Data with PCSK9 Inhibitors Show Cardiovascular Risk Reductions in Line with LDL Control

Randomized Comparison Distinguishes PPIs for Relative Effect on Antiplatelet Agent Activity